<- Go Home
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Market Cap
GBP 4.6B
Volume
457.5K
Cash and Equivalents
GBP 236.0M
EBITDA
GBP 764.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
GBP 1.4B
Profit Margin
43.03%
52 Week High
GBP 31.24
52 Week Low
GBP 20.15
Dividend
4.08%
Price / Book Value
1.79
Price / Earnings
12.33
Price / Tangible Book Value
3.45
Enterprise Value
GBP 5.9B
Enterprise Value / EBITDA
7.61
Operating Income
GBP 580.0M
Return on Equity
15.38%
Return on Assets
6.97
Cash and Short Term Investments
GBP 236.0M
Debt
GBP 1.6B
Equity
GBP 2.6B
Revenue
GBP 3.2B
Unlevered FCF
GBP 172.5M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium